Showing 1511-1520 of 2152 results for "".
- Rayner Announces First RayOne Galaxy Implantations in the UShttps://modernod.com/news/rayner-announces-first-rayone-galaxy-implantations-in-the-us/2482467/Rayner has announced the implantation of the first IOL in the RayOne Galaxy FDA-approved investigational device exemption (IDE) study. This milestone marks the beginning of a prospective, multicenter, randomized, masked, and active-controlled study aimed at evaluating the RayOne Galaxy
- Eyenovia Launches Clobetasol for Postoperative Ocular Surgery Pain and Inflammationhttps://modernod.com/news/eyenovia-launches-clobetasol-for-postoperative-ocular-surgery-pain-and-inflammation/2482460/Eyenovia announced the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, which is designed to address postoperative inflammation and pain following ocular surgeries. The FDA approval and launch marks the first new ophthalmic steroid to be a
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481917/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The approval for RVO marks the third indication for Vabysmo, along with wet age-related macular degeneration (AMD) and diabetic macular edem
- Endogena Therapeutics Secures FDA Green Light to Initiate Trials for Geographic Atrophy Treatmenthttps://modernod.com/news/endogena-therapeutics-secures-fda-green-light-for-breakthrough-amd-treatment/2481909/Endogena Therapeutics announced that the FDA has granted clearance for Endogena's investigational new drug (IND) application, allowing the company to commence a first-in-human study in 2024 for its geographic atrophy drug cadidate EA 2351. This milestone marks the com
- Heidelberg Engineering Receives FDA Clearance for Anterion Platformhttps://modernod.com/news/heidelberg-engineering-announces-fda-clearance-of-anterion-platform/2481889/Heidelberg Engineering has received FDA clearance of its Anterion platform, designed to improve anterior segment diagnostics and streamline practice workflow. “Building upon our previous CE-marking, we are thrilled that the Anterion platform is
- ESCRS Releases the 2022-2023 EUREQUO Annual Reporthttps://modernod.com/news/escrs-releases-the-2022-2023-eurequo-annual-report/2481801/The European Society of Cataract & Refractive Surgeons (ESCRS) has released the 2022-2023 EUREQUO annual report. ESCRS is marking the 15th anniversary of the establishment of the EUREQUO Registry with the announcement that the cataract and refractive database has grown to more than 4 mil
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- Norlase Secures $11M in New Funding Following Regulatory Clearance of ECHO Pattern Laserhttps://modernod.com/news/norlase-secures-11m-in-new-funding-following-regulatory-clearance-of-echo-pattern-laser/2481634/Norlase announced it has secured $11 million in funding, its largest investment round thus far. Norlase said the funding will enable it to accelerate the production ramp-up of the ECHO pattern laser, which just received FDA clearance and CE Mark earlier this month, as well as